Victoza Related Published Studies
Well-designed clinical trials related to Victoza (Liraglutide)
Liraglutide: a review of its use in the management of type 2 diabetes mellitus. [2011.12.03]
The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects. [2011.12]
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. [2011.08.16]
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. [2011.08]
Review of the therapeutic uses of liraglutide. [2011.07]
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. [2011.07]
Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. [2011.06]
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. [2011.04]
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. [2011.03]
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. [2011.03]
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. [2011.03]
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). [2011.01]
The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a
once-daily human GLP-1 analogue, after multiple subcutaneous administration in
healthy Chinese male subjects. [2011]
[Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)]. [2010.09]
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. [2010.07]
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. [2010.07]
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. [2010.06]
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. [2010.05]
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. [2010.04.24]
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. [2009.11.07]
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. [2009.11]
Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. [2009.11]
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. [2009.10]
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). [2009.07.04]
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). [2009.07]
Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. [2009.05]
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). [2009.03]
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. [2009.02.07]
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. [2009.01]
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. [2008.08]
Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. [2008.06]
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. [2008.02]
Well-designed clinical trials possibly related to Victoza (Liraglutide)
Efficacy and safety of incretinbased therapies: clinical trial data. [2009.09]
Other research related to Victoza (Liraglutide)
Exenatide once weekly versus liraglutide once daily in patients with type 2
diabetes (DURATION-6): a randomised, open-label study. [2013]
Comparison of liraglutide versus other incretin-related anti-hyperglycaemic
agents. [2012]
Liraglutide in oral antidiabetic drug combination therapy. [2012]
The design of the liraglutide clinical trial programme. [2012]
An overview of the pharmacokinetics, efficacy and safety of liraglutide. [2012]
THE ROLE OF GLP-1 MIMETICS AND BASAL INSULIN ANALOGUES IN TYPE 2 DIABETES MELLITUS: GUIDANCE FROM STUDIES OF LIRAGLUTIDE. [2011.11.03]
Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >/=65 and <65 Years of Age: A Pooled Analysis from Phase III Studies. [2011.11.02]
Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. [2011.11]
Next-generation GLP-1 therapy: an introduction to liraglutide. [2011.09]
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. [2011.08.29]
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. [2011.08.22]
The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice. [2011.07.29]
Liraglutide as additional treatment for type 1 diabetes. [2011.07]
[Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes]. [2011.06.27]
Place in therapy for liraglutide and saxagliptin for type 2 diabetes. [2011.06]
Mild renal impairment and the efficacy and safety of liraglutide. [2011.05]
Liraglutide for the treatment of type 2 diabetes. [2011]
Review of the therapeutic uses of liraglutide. [2011]
Liraglutide improves treatment satisfaction in people with Type 2 diabetes
compared with sitagliptin, each as an add on to metformin. [2011]
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? [2010.04]
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. [2010.04]
Liraglutide. [2010.04]
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. [2010.03.01]
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. [2010.02.25]
Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. [2010.01]
Patient-reported outcomes in patients with type 2 diabetes treated with
liraglutide or glimepiride, both as add-on to metformin. [2010]
The future use of liraglutide: implications of the LEAD-2 study for treatment
guidelines in type 2 diabetes. [2010]
Improved glycaemic control with minimal hypoglycaemia and no weight change with
the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to
sulphonylurea in Japanese patients with type 2 diabetes. [2010]
Switching to once-daily liraglutide from twice-daily exenatide further improves
glycemic control in patients with type 2 diabetes using oral agents. [2010]
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. [2009.12]
Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. [2009.12]
Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. [2009.12]
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. [2009.12]
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. [2009.11]
[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2] [2009.11]
Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. [2009.08]
Other possibly related research studies
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. [2010]
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. [2010.08]
Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. [2010.07]
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. [2010.09]
Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. [2010.06]
[New hypoglycemic agents in type 2 diabetes] [2010.04.20]
Gateways to clinical trials. [2010.04]
Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1. [2010.08.01]
Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. [2010.04]
Association of pancreatitis with glucagon-like peptide-1 agonist use. [2010.05]
Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. [2010.06]
Pharmacological management of appetite expression in obesity. [2010.05]
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. [2010.03]
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. [2010.04]
Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. [2010.01]
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. [2010.01]
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. [2010.01]
The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. [2009.12]
Beyond glycemic control: treating the entire type 2 diabetes disorder. [2009.09]
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. [2009.09]
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. [2011.11]
Glucagon-like peptide analogues for type 2 diabetes mellitus. [2011.10.05]
Recent diabetes issues affecting the primary care clinician. [2011.06]
Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. [2011.08.02]
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. [2011.07]
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. [2011.05]
GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. [2011.08]
[Treatment of type 2 diabetes mellitus with GLP-1 agonists]. [2011.04]
Effects of glucagon-like peptide-1 receptor agonists on body weight: a
meta-analysis. [2012]
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in
development for treatment of type 2 diabetes mellitus in adults. [2012]
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists
compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus:
a systematic review and meta-analysis. [2011]
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2
diabetes: a review. [2011]
|
